switch to the mucoid phenotype, characterized by over-production of high molecular weight (Mw; >15 kDa) alginate exopolysaccharide (EPS) (7, 8) . This switch is accompanied by modification of acyl homoserine lactone (AHL) and Pseudomonas quinolone signal (PQS)dependent quorum sensing (QS) systems (λ) , with altered production of virulence factors e.g. pyocyanin and hydrogen cyanide (10) . Extracellular alginate affords protection from host innate immune-responses, including phagocytosis and neutrophil-derived reactive oxygen species (11) . Mucoidal pseudomonal strains are often un-responsive to aggressive antibiotic selection (12) and 18.1% of CF patients are colonized with multi-drug resistant (MDR) P. aeruginosa (13) .
In contrast to standard laboratory models of bacterial biofilm formation on material surfaces, biofilms within the CF lung form as non-adherent spherical microcolonies, embedded in respiratory mucin (14, 15) . Whilst in vitro studies of P. aeruginosa from CF lungs routinely employ nutrient-rich media to optimize bacterial growth, or Mueller-Hinton (MH) medium, such media fail to adequately reproduce the lung environment or secretome (3) . More recently, defined media such as artificial sputum (AS) medium (containing components of CF sputum e.g. DNA, mucin, mineral salts, proteins and amino acids) have been employed to model the behavior of P. aeruginosa (16) (17) (18) . These AS medium models have been used to study the adaptation of pathogens to the CF lung using whole-genome sequencing and microarray expression profiling (1λ) , analyze diffusion (20) and test the effectiveness of antibacterial therapeutics (21) .
This distinctive biofilm microcolony formation in the CF lung has been demonstrated exvivo in freshly-excised intraluminal material and in lung sections (14) . Studies have also further shown that in vitro biofilms observed in nutrient-limited conditions are increasingly recalcitrant to antibiotic therapy due to enhanced tolerance (22) . The design and delivery of antimicrobial therapy targeted against the polymicrobial respiratory biofilm is, therefore, challenging (23) .
The acquisition of MDR Pseudomonas in the CF lung has led to a resurgence of clinical interest in the bacteriocidal antibiotic colistin (24) . Overlooked for many years due to associated nephro-and neuro-toxicity (25, 26) , colistin is increasingly used to treat lifethreatening infections (24) and as an inhaled therapy in CF to prevent establishment of infection by MDR bacteria (25) . While resistance to colistin remains low (27) , the emergence of colistin-resistant strains heralds fears of a post-antibiotic era (28) .
We previously described the use of a low molecular weight alginate oligomer (OligoG CF-5/20, ≥ 85% guluronic acid, with a degree of polymerization [DPn] of 16; Mn 3,200) from the seaweed Laminaria hyperborea as a promising novel therapy in CF (2λ-31) . In vitro studies, demonstrated the ability of OligoG CF-5/20 to modify bacterial surface charge (30) and biofilm growth of non-mucoid Pseudomonas sp. in conventional culture/biofilm models (2λ) . It is however, important to determine whether OligoG CF-5/20 could modify bacterial growth within the inherently antibiotic-resistant microcolonies, which characterize the diseased CF lung.
The objective of this study was to investigate the therapeutic efficacy of OligoG CF-5/20 and colistin in an in vitro microcolony model. We characterized the growth of fresh clinical isolates from CF patients and strains from the International P. aeruginosa Reference Panel (IPARP) . Planktonic and biofilm cultures of wild-type PAO1 and the mucoid MDR NH57388A were studied in MH and AS media. We developed microcolonies in the AS medium and investigated the ability of OligoG CF-5/20 to modify these biofilms and further determined the effectiveness of a combination treatment with colistin. The effect of colistin on the mucoid CF isolate NH57388A grown under planktonic and biofilm conditions was reduced in this AS medium. In contrast, OligoG CF-5/20 retained its dose-dependent antibiofilm properties, as well as maintaining the effectiveness of colistin in vitro, demonstrating that addition of alginate oligosaccharides modifies pseudomonal microcolony assembly.
RESULTS

Non-mucoid P. aeruginosa IPARP have faster growth rates in MH medium than either mucoid or new non-mucoid CF isolates
Growth of non-mucoid P. aeruginosa in MH medium from the IPARP reference strains was more abundant (maximum absorbance ≥1) compared to the delayed, weaker growth of the fresh clinical isolates (maximum absorbance ≤1); acquiring stationary phase at 12 h versus 20 h respectively ( Fig. 1A) . The growth rates of the non-mucoid P. aeruginosa (PAO1, AA2, AA44) were also greater than those of the new CF Isolates (22476, 22078, 22554) and those of the mucoidal strains (AA43, IST27, 21λ2, NH57388A) from the IPARP collection ( Fig. 1B) having doubling-times (at maximum exponential growth) of 0.2-0.23 versus 0.31-0.6 versus 0.2λ-0.56 unit/h respectively.
Colistin maintains its antimicrobial properties in the presence of the mucolytic OligoG
CF-5/20
Initial studies on the effect of OligoG CF-5/20 and colistin (0.5x minimum inhibitory concentration [MIC] value) on pseudomonal growth in MH medium, demonstrated no difference in the growth rate of NH57388A when treated with colistin (0.16 unit/h) compared to the control (Fig. 1C) , although a reduced growth rate (0.12 unit/h) was noted when treated with either 2% OligoG CF-5/20 or colistin with 2% OligoG CF-5/20. This was reflected by the significantly decreased cell biomass at stationary phase (36 h) following treatment with 2%
OligoG CF-5/20 in combination with colistin compared to the control (p<0.05).
In the biofilm disruption assay, confocal laser scanning microscopy (CLSM) images of LIVE/DEAD ® -stained, 24 h established pseudomonal biofilms demonstrated homogenous growth in the untreated control ( Fig. 1D) . Treatment for 1 h with colistin alone at 0.5x the minimum biofilm eradication concentration (MBEC value as previously described [32] ) was associated with a decreased density of the resultant biofilm ( Fig. 1E) . Furthermore, when treated with 2% OligoG CF-5/20 alone for 1 h, the biofilm height was reduced and there was increased porosity (Fig. 1F) . Combination treatment of colistin and 2% OligoG CF-5/20 resulted in marked biofilm disruption ( Fig. 1G) . Quantification using COMSTAT image analysis software (33) revealed that biofilm height was significantly reduced from 11 ±4 µm (in the untreated control) to 1.1 ±0.2 µm following 2% OligoG CF-5/20 and colistin combination treatment (Fig. 1H) . In parallel, the ratio of dead to live cells was significantly increased following treatment with colistin (0.24 ±0.07) or 2% OligoG CF-5/20 and colistin in combination (0.4λ ±0.22) compared to the control (0.053 ±0.014; p<0.05; Fig. 1I ); with associated increases in porosity.
Mucoid and non-mucoid P. aeruginosa show a distinctly altered biofilm phenotype in artificial sputum medium
Biofilms grown in different nutrient media exhibited distinct patterns of growth, with a marked phenotypic difference in biofilm architecture in MH-versus AS medium ( Fig. 2A-B ; diagrammatic representation Fig. 2C ). Pseudomonal biofilms of both strains showed conventional homogenous growth in MH medium, whilst discrete, spherical microcolonies with an inter-linking network of extracellular polysaccharide (EPS) were apparent in AS medium. Microcolonies were not strongly bound to the well plates and varied considerably in size. The median diameter of the PAO1 and NH57388A microcolonies was 14 ± 4 µm and 11 ±5 µm respectively; the difference in size perhaps reflecting the slower growth rate of the mucoid strain. Elongated structures between the microcolonies were composed of linearly arranged bacterial cells.
Growth curves were performed using a cell-viability assay, (measuring ATP production); conventional growth curves with optical density measurements being impractical in AS medium, due to bacterial aggregation and microcolony formation. Marked differences in ATP production between cells grown in AS versus MH medium were evident within 24 h, being considerably elevated in AS medium ( Fig. 2D) . 3D videos of these images are available online (Supplementary information Video 1).
Circular dichroism spectra of OligoG CF-5/20 mixed with high molecular weight pseudomonal alginate do not indicate a specific interaction
Circular dichroism (CD) spectroscopy was used to test whether OligoG CF-5/20 and the high molecular weight EPS alginate produced by mucoid pseudomonal strains show a specific interaction. The CD chromophore responsible for the Cotton effect observed at ca. 210 nm has been identified as the carboxyl groups of the alginates, and the n → π* transition reflects their orientation (34) . Upon heating from 4 to 37°C, spectra of high Mw alginate showed no changes over a period of ~80 min (Fig. 4A , scans 1 to 7). Subsequent addition of OligoG CF-5/20 at a 50-fold molar excess resulted in an increased CD amplitude, i.e. more negative values ( Fig. 4A , scans 8 to 11). Addition of Ca 2+ to a final concentration of 1 mM had no effect ( Fig. 4A, scans 12 
OligoG CF-5/20 affects cell-signaling in pseudomonal biofilms
To determine whether OligoG CF-5/20 affected these changes via modification of QS signaling in the biofilm systems, liquid chromatography/mass spectrometry (LC/MS) was employed to detect the pseudomonal signaling molecules, C4-and 3-oxo-C12-acyl homoserine lactones (AHLs). AHL levels were determined at 30 and 48 h for PAO1 cells grown in both MH and AS medium. Initial experiments compared growth in MH and AS medium at 30 h (as at earlier time points in AS medium, AHLs were at the limits of detection; results not shown). LC/MS values indicated a reduction in the production of both 3-oxo-C12-AHL and C4-AHL signaling molecules in AS medium (62 and 783 fold respectively) compared to MH medium ( Fig. 4B) . Further experiments were performed on OligoG CF-5/20-treated cultures grown in AS medium for 30 and 48 h (corresponding to mid-and latestationary phase respectively; results not shown). Interestingly, in this model it was evident that OligoG CF-5/20 (0.2-2%) induced a dose-dependent decrease in 3-oxo-C12 AHL (produced by the Las pathway) in comparison to the control at 30 and 48 h ( Fig. 4C) , but did not induce any significant change in C4-AHL (produced by the RhlI pathway; Fig. 4D ).
Although OligoG CF-5/20 had a significant effect on biofilm formation, there was no marked difference in ATP production (cell viability) by PAO1 or NH57388A following treatment ( Fig.   4E and 4F) .
The antibiotic properties of colistin were retained in artificial sputum medium when combined with OligoG CF-5/20
Assays of biofilm disruption in established (24 h) non-mucoid (PAO1) and mucoid (NH57388A) pseudomonal biofilms following 24 h treatment with OligoG CF-5/20 and/or colistin were investigated in AS medium. The observed MIC value for colistin was 4x greater in AS medium (0.4 µg/ml versus 0.1 µg/ml) compared to MH medium. The MIC employed in subsequent studies was based upon these findings.
As observed previously, PAO1 and NH57388A demonstrated the formation of large numbers of spherical microcolonies, with extensive EPS in this model ( Fig. 5A, 5B) . The mucoidal NH57388A biofilms were characterized by smaller microcolonies when compared to PAO1 (median diameter 11 µm versus 14 µm respectively) ( Fig. 5C, 5D ). Biofilm treatment with colistin (at x4 the MBEC value (32), induced disruption of PAO1 and NH57388A bacterial networks. The microcolonies, however, remained intact (with no change in median diameter; p>0.05). In contrast, treatment with 2% OligoG CF-5/20 induced significant decreases in the median microcolony diameter (6.λ ±2.0 µm and 6.1 ±2.7 µm; PAO1 and NH57388A respectively; p<0.05) characterized by marked disruption of the inter-colony networks and microcolony morphology. Combining OligoG CF-5/20 with colistin (although not as effective as OligoG CF-5/20 alone on the mucoid strain) effectively disrupted both microcolony structure (reducing the median diameter by 60% in PAO1) as well as the inter-colony branching/bridging in both mucoid and non-mucoid models. Overall structural differences can be seen at a lower magnification in Fig. S2 .
DISCUSSION
The improved survival of CF patients, due in part to the chronic administration of antibiotics, has compounded the problems associated with resistance to antibiotic treatment (35, 36) .
With the rapid emergence of antibiotic resistance, the development of new therapies is essential. Increased antibiotic resistance in biofilms has been extensively described, with biofilms shown to resist antibiotics by up to 1000 fold (37) . These studies demonstrate the potential benefits of combination therapies using a novel mucolytic alongside conventional antibiotics in the treatment of antibiotic-resistant, microcolony-forming Pseudomonas sp.
lung Infections.
The resurgence of interest in colistin, a highly-effective membrane-permeabilizing antibiotic, reflects the failure of conventional antibiotics in MDR infections (25) .
Unfortunately, the emergence of plasmid-mediated colistin resistance provides the imminent possibility for horizontal gene transfer from veterinary to human pathogens (38) . Due to the high rate of MDR in P. aeruginosa (3λ) colistin is now regarded as an antibiotic of 'last resort' and its use (in non-CF patients) is therefore limited to prevent further development of resistance (40) .
Colistin acts through positively-charged electrostatic interactions with the negativelycharged bacterial lipopolysaccharide (LPS), facilitating membrane disruption. The observed lowering of the efficacy of colistin in AS medium may, therefore, not only relate to an altered growth rate in this environment, (which mimics growth conditions in the CF lung), but also may be due to LPS modification and/or direct binding by mucin in the AS medium, effectively 'sequestering' free antibiotic (41) . This EPS effect, and the apparent differences in MIC for colistin-treated NH57388A, (with MIC values being 4X greater in AS versus MH medium) reflect the 10 4 -fold difference previously observed between MIC (0.0λ4 µg/ml) and MBEC (>512 µg/ml) values for NH57388A in vitro (42) .
Within the diseased CF lung, >λ5% of P. aeruginosa exist in dense microcolonies, >5 µm from the epithelial cell-surface and independent of cell-surface attachment (14, 43) . The microcolonies develop in the early stages of lung infection and readily resist physical disruption (43) . The AS medium employed here induced pseudomonal microcolony formation in both non-mucoid and mucoid strains as seen previously. These microcolonies resembled those observed in a range of CF epidemic and non-epidemic P. aeruginosa strains (16) ; SEM demonstrating bridges between the microcolonies which appeared to be composed of elongated single-cells encased in EPS, as previously observed in flow-cell systems (44) . OligoG CF-5/20 was able to modulate both the size and structure of these bacterial microcolonies. This may relate to its ability to interact with the EPS component of the biofilm, by direct effects on the pseudomonal bacterial cell-surface, and on bacterial growth (2λ, 30) . Whilst imaging studies demonstrated that colistin effectively disrupted the inter-colony bridges, the microcolonies (which were encased in EPS) appeared unaffected by colistin alone.
Despite the possible charge interactions between the cationic peptide colistin (41) and the anionic OligoG CF-5/20 (30) , colistin retained its antibiotic activity in the presence of OligoG CF-5/20. The ability of OligoG CF-5/20 to modify biofilm assembly in Pseudomonas spp. has previously been attributed to irreversible binding at the bacterial cell surface (30) .
Moreover, the ability of OligoG CF-5/20 to potentiate the effectiveness of colistin against mucoid NH57388A biofilms by OligoG CF-5/20 has recently been demonstrated in MBEC assays (32) .
In this model, the ability of OligoG CF-5/20 (both alone, and more markedly with colistin) to effectively disrupt the EPS of established biofilms was clearly evident. Disruption of the tight EPS-network, which comprises >λ0% of the biofilm dry-weight (45) , has been shown to lead to less mechanically-stable biofilms, which are then more susceptible to antibiotics (46) . It appears therefore that EPS disruption by OligoG CF-5/20 maintained the antimicrobial action of colistin by reducing its ability to bind to components of the biofilm matrix, thereby increasing its penetration through the biofilm, facilitating access of colistin to the pseudomonal cell membrane.
Initial experiments demonstrated the contrasting growth phenotype between freshly isolated clinical strains compared to the well-characterized reference strains. Compensatory mutations in the clinical CF isolates are thought to provide differential fitness benefits, which are advantageous within the CF lung environment (47) . Fitness 'trade-offs', where beneficial adaptations that improve fitness under one environmental condition that may lead to compensatory loss of other traits have been described (48) . This may, in part, explain the observed lower growth rate of fresh clinical isolates (adapted to the CF lung) when compared to the laboratory-maintained IPARP CF strains. This variability highlights the importance of utilizing the reference strain collection for therapeutic development to ensure global standardization of in vitro testing.
A number of approaches have been attempted to modify biofilm EPS and facilitate treatment or displacement therapy. These have includedμ use of bacterial polysaccharides e.g. from marine Vibrio sp. (4λ); co-administration of alginate lyase with DNase, which has been reported to increase the efficacy of antibiotics in reducing biofilm growth (50) and coadministration of antibiotics with alginate lyase to eliminate mucoid variants not affected by antibiotics alone (51) . Interestingly, we have also previously demonstrated synergy between
OligoG CF-5/20 and rhDNase I in modifying the mechanical and structural properties of CF sputum (31) .
Biofilms also contain bacterially-derived alginates which, in contrast to OligoG CF-5/20, lack G-blocks and have a considerably higher molecular mass (52) . Anionic EPS components, such as carboxyl groups, interact strongly with multivalent cations such as Ca 2+ , resulting in robust biofilms (53) . Sletmoen et al., (2012) demonstrated that alginate oligomers may destabilize the interaction between high Mw bacterially-produced alginates and mucin. The ionic displacement of divalent cations e.g. Ca 2+ has been described as a mechanism by which antimicrobial cationic peptides can potentiate antibiotics (54) .
Similarly, the anionic alginate G-blocks may displace divalent cations associated with the biofilm, resulting in a weaker biofilm structure. CD spectroscopy has previously been used to investigate the structural and conformational changes of polysaccharides containing uronic acid residues, and has recently been employed to characterize homopolymeric fractions of the linear co-polymers L-guluronate and D-mannuronate (34, 55) . The gelation of alginate in the presence of divalent cations such as Ca 2+ in homopolyguluroinc acid is known to induce changes in the coordination of the carboxylate groups (56) . However, CD spectra indicated that the orientation of the carboxy groups monitored at ~210 nm were not changed upon mixing OligoG CF-5/20 with high Mw alginate.
Previous studies in planktonic systems demonstrated that OligoG CF-5/20 modified both pilE gene expression and bacterial motility in Pseudomonas aeruginosa (30) , which are controlled by QS. The finding that levels of P. aeruginosa AHL signaling molecules were significantly reduced in AS medium compared to MH medium was perhaps unsurprising, reflecting the change in growth/morphology. Sriramulu et al (2005) , demonstrated the importance of lasR for the formation of the dense microcolony phenotype and these data demonstrated the ability of (>2%) OligoG CF-5/20 to significantly reduce 3-oxo-C12-AHL production at both mid-and late-stationary phase growth (30 and 48 h). The lack of an observed effect on the Rhl product, C4-AHL, may reflect the reduced expression of rhlR which is known to occur in AS medium (16) .
These experiments demonstrate that the previously described antibacterial effects of OligoG CF-5/20, are evident in this pseudomonal microcolony assay system which more closely resembles growth in the CF lung. It must be remembered that many of the components of the in vivo lung are absent in the biofilm model, including lactoferrin, lipids and oligopeptides, which may modulate bacterial behavior in vivo. OligoG CF-5/20 was shown to disrupt the biofilm EPS network and, in combined respiratory therapies, this inhaled treatment may facilitate increased access of therapeutic agents to bacteria and/or the lung cell-surface. The mechanistic studies showed that this disruption of EPS structure was not simply related to interaction between the OligoG CF-5/20 and the pseudomonal (Mblock alginate), but may rather reflect modification of QS signaling within the biofilm. The findings here, and the proven safety of the agent as an inhalational therapy (www.clinicaltrials.gov, Identifierμ NCT00λ70346 and NCT0146552λ), highlight the potential utility of this agent in the treatment of MDR bacterial infections in a range of human diseases. Phase IIb human studies are currently ongoing (www.clinicaltrials.gov, Identifierμ NCT02157λ22 and NCT0245378λ).
METHODS
Bacterial strains and media
P. aeruginosa strains were cultured on blood agar plates and grown overnight in Tryptone soy broth (TSB; LabM), at 37°C. Mueller Hinton (MH) medium or Artificial Sputum (AS) medium (adapted from earlier studies [43] by supplementation with 20 ml/L RPMI 1640 as an amino acid source; Sigma Aldrich) were also employed.
Reference strains (n=7) were obtained from the International P. aeruginosa Reference Panel (IPARP) (57) includingμ AA2 and AA44 (early and late non-mucoid CF colonizers respectively); AA43 (mucoidal colonizer from the same AT code) and mucoidal CF isolates, IST 27 (Lisbon, Portugal) and 21λ2 (source ID; Boston, MA). The well characterized non-mucoid PAO1 and mucoidal MDR CF strain NH57388A (Copenhagen, Denmark), were also used in subsequent experiments. 
Patients and clinical isolates
Changes in antibiotic susceptibility in the different media
Bacteriocidal values for colistin in MH and AS medium were studied using standard minimum inhibitory concentration (MIC) assays as previously described (2λ) . 
Effects of OligoG CF-5/20 on pseudomonal growth in the presence of colistin
Viable microbial cell numbers in culture when treated with OligoG CF-5/20
Adenosine triphosphate (ATP) production by PAO1 and NH57388A was compared in MH and AS medium ± 2% OligoG CF-5/10. Cultures were prepared as for the growth curve experiments and analyzed using the BacTiter-Glo™ Microbial Cell Viability Assay (Promega) at 0, 2, 4, 6, 8, 12, 24 and 48 h with luminescence read on a FLUOstar Omega plate reader.
Confocal laser scanning microscopy biofilms in MH and AS media in the presence of
OligoG CF-5/20
Pseudomonal cultures (NH57388A) standardized to 10 7 cfu/ml, were inoculated 1μ20 in MH or AS media and incubated (37°C; 20 rpm) for 24 h or 48 h respectively in Greiner glass-bottomed optical λ6-well plates; the difference in growth rates in the two media, accounting for the longer growth time used for the AS medium. For antimicrobial treatment, half of the supernatant was gently removed and replaced with fresh MH or AS medium ± 2%
OligoG CF-5/20 and/or colistin at half the MBEC (2 µg/ml) and incubated for 1 h. Supernatant was then removed and replaced with 6% (v/v) LIVE/DEAD ® (Invitrogen) stain in PBS prior to imaging. CLSM was performed using a Leica SP5 confocal microscope with x63 magnification under oil. Z-stack CLSM images were analyzed using COMSTAT image analysis software (33) .
AS medium biofilms were also fixed overnight at 4°C with 3% (v/v) glutaraldehyde and stained (1 h The column was equilibrated in 2% B before increasing in a linear fashion to 100% over 6 mins. 100% B was maintained for a further 2 min before column re-equilibration. The column temperature was maintained at 35°C for the duration with a flow rate of 0.3 mL/min. Source parameters were set as followsμ Temperature, 350°C; gas flow, 10 L/min; nebulizer, 35 psi; and capillary voltage, 4 kV. Data was analysed using Agilent MassHunter QQQ Quantitative Analysis software (Version B.07.00). Peak areas were normalized to the internal standard umbelliferone and concentrations calculated using standard concentration curves, offset against blank values (the average peak areas for the blanks).
Statistical analysis
The COMSTAT data was normally distributed so a standard t-test was performed using 
